Lv3
326 积分 2024-06-03 加入
Moving towards a new era for the treatment of neuromyelitis optica spectrum disorders
14小时前
已完结
Prescription of oral antidiabetic drugs in K/DIGO chronic kidney disease stage 3 and 4: a single centre report
1天前
已关闭
The impact of enzyme replacement therapy on the oral health manifestations of hypophosphatasia among children: a scoping review
6天前
已完结
Safety and efficacy of ravulizumab in patients with NMOSD previously treated with rituximab: A post hoc analysis of the CHAMPION-NMOSD trial
8天前
已关闭
Safety and efficacy of the selective tyrosine kinase 2/Janus kinase 1 inhibitor TLL-018 in moderate-to-severe plaque psoriasis: a phase Ib, randomized, double-blind, placebo-controlled study
10天前
已完结
Safety and efficacy of the selective tyrosine kinase 2/Janus kinase 1 inhibitor TLL-018 in moderate to severe chronic spontaneous urticaria patients with inadequate response to H1 antihistamines: a phase Ib, randomized, double-blind, placebo-controlled pilot study
10天前
已完结
Overall Survival with Amivantamab–Lazertinib in EGFR-Mutated Advanced NSCLC
17天前
已完结
Survival with Amivantamab–Lazertinib in EGFR-Mutated NSCLC
17天前
已关闭
Amivantamab plus Lazertinib in Previously Untreated EGFR -Mutated Advanced NSCLC
17天前
已关闭
皖公网安备34019202002308
